ENVB - Company ID 0000890821
The table below shows Enveric Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | - | - | - | - | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.79M |
| $5.38M |
| $4.17M |
| $3.31M |
| $4.83M |
| $4.34M |
| Property, plant & equipment | $81.93K | $119.93K | $196.52K | $241.08K | $267.28K | $367.69K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $8.94M | $5.52M | $4.36M | $3.55M | $5.10M | $4.79M |
| Accounts payable | $682.79K | $280.31K | $683.71K | $1.04M | $669.19K | $576.32K |
| Total current liabilities | $861.48K | $460.68K | $905.88K | $1.36M | $1.18M | $839.17K |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$119.51M | -$116.48M | -$112.65M | -$110.78M | -$108.26M | -$102.92M |
| Total equity | $8.08M | $5.06M | $3.46M | $2.18M | $3.92M | $3.95M |